Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00676533 · ClinicalTrials.gov registry record · Phase 4
Cipro® XR in Therapeutic Response and Activity (eXtRa) - Assessing Symptom Relief in Urinary Tract Infections
A Phase 4 study, sponsored by Bayer.
- Completed
- Registry status
- Phase 4
- Development phase
- 276
- Enrollment target
NCT00676533: Completed Phase 4 study, sponsored by Bayer.
NCT00676533 is a Phase 4 study that has completed, run by Bayer. The registered enrollment target is 276 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (47% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00676533, a Phase 4 study, has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 276 participants
- Enrollment target
Study Summary
The primary objective of this clinical trial was to determine the time to improvement of the signs and symptoms (eg, dysuria, frequency, urgency, gross hematuria, suprapubic pain, hesitancy, low back pain) of acute, uncomplicated, symptomatic, lower UTIs in women treated with Cipro XR 500 mg once daily for 3 days.
Interventions
- DRUG Cipro XR (Ciprofloxacin, BAYQ3939)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 276 participants |
| Start Date | 2003-06 |
| Est. Completion | 2004-01 |
| Phase | Phase 4 |
What the finished NCT00676533 record still lists
NCT00676533 is an interventional study that assigns participants to a tested intervention. The registered 276 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (47% lower).
The record links to 0 conditions, and to 1 intervention - of which Cipro XR (Ciprofloxacin, BAYQ3939) is the first listed.
NCT00676533 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00676533 about?
NCT00676533 is a clinical study titled "Cipro® XR in Therapeutic Response and Activity (eXtRa) - Assessing Symptom Relief in Urinary Tract Infections". The primary objective of this clinical trial was to determine the time to improvement of the signs and symptoms (eg, dysuria, frequency, urgency, gross hematuria, suprapubic pain, hesitancy, low back pain) of acute, uncomplicated, symptomatic, lower UTIs in women treated with Cipro XR 500 mg once da...
What is the current status of trial NCT00676533?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 276 participants. The study started on 2003-06. Estimated completion is 2004-01.
What interventions are being tested in trial NCT00676533?
The interventions under investigation include: Cipro XR (Ciprofloxacin, BAYQ3939) (DRUG).
Who is sponsoring clinical trial NCT00676533?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00676533's enrollment target sits among peer trials
276 310th of 2000 higher than 1,690 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01371630 · 276 participants · Phase 1
Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia
- NCT04192344 · 276 participants · Phase 1
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK-021 in Patients With Advanced Solid Tumor
- NCT05294991 · 276 participants · NA
Wellness App for Sleep Disturbance in Hematological Cancer Patients
- NCT05610852 · 276 participants · NA
Single-Port Transvesical Partial Prostatectomy Versus High Intensity Focused Ultrasound
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia